Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Patients were mainly treated by TNF inhibitors in 58.9%, by NSAIDs in 67.1%, and only 9.6% by corticosteroids (Table 1).Demographical, clinical characteristics and bone assessment on CT of the 73 AS patients according to spine structural involvement (mSASSS or vertebra ankylosis).All patientsn = 73mSASSS + n = 60mSASSS: n = 13pmSASSS + Bone bridge + Bone bridge: pn = 37n = 23Demographic and clinicAge (n = 73)60.3 (60)62 (61)52.7 (57)0.49362 (57.5 to 73)59 (53 to 67)0.88Men (n = 73)65 (89)53 (88.3)12 (92.3)0.67734 (91.9)19 (82.6)0.276Smoker (n = 48)31 (42.5)25 (41.7)6 (46.2)0.517 (45.9)8 (34.8)0.931Alcool (n = 28)4 (5.48)4 (6.7)0 (0)0.6784 (10.8)0 (0)0.160AS characteristicsDisease duration (n = 71)24 (12 to 34)25 (13 to 35)15.5 (12 to 25.25)0.07627 (13.75 to 35.75)24 (11 to 35)0.529BASFI (n = 58)43.5 (23.7)44.5 (22.2)41.2 (30.8)0.59846.7 (22.2)42 (22.4)0.319BASDAI (n = 62)7.2 (10.5)7.1 (10.5)8.4 (11.3)1.07.2 (12.7)6.9 (7.3)0.236ASDAS (n = 21)3.4 (1.2)3.4 (0.9)3 (2.6)0.7633.7 (1)2.81 (0.6)0.035HLA B27 (n = 69)46 (63)39 (65)7 (53.8)0.27626 (70.3)13 (56.5)0.075Biological inflammation CRP (n = 69)31 (42.5)28 (46.7)3 (23.1)0.07918 (48.6)10 (43.5)0.415mSASSS on radiographs (n = 73)20.7 (21.2)25.1 (20.8)0 (0)0.000137.2 (17.8)5.9 (4.2)0.0001TreatmentsCorticosteroids (n = 49)7 (9.6)5 (8.3)2 (15.4)0.2433 (8.1)2 (8.7)0.926NSAIDs (n = 51)49 (67.1)44 (73.3)5 (38.5)0.63430 (81.1)14 (60.9)0.048Proton Pomp Inhibitor (n = 15)15 (20.5)14 (23.3)1 (7.7)/9 (24.3)5 (21.7)/TNF inhibitor (n = 43)43 (58.9)36 (60)7 (53.8)/23 (62.2)13 (56.5)/Vitamin D and/or calcium (n = 73)18 (24.6)14 (23.3)4 (30.8)0.5739 (24.3)5 (21.7)0.818Specific treatment for osteoporosis (n = 72)12 (16.4)9 (15)3 (23.1)0.4938 (21.6)1 (4.3)0.063SBAC-L1Mean (SD) in HU141.1 (45)138.1 (44.8)154.8 (44.9)0.239123.96 (41.1)160.4 (41.9)0.002Fracture threshold (145 HU)42 (57.5)36 (60)6 (46.2)0.32527 (73)9 (39.1)0.006VFNumber of patients9 (12.3)8 (13.3)1 (7.7)0.5755 (13.5)3 (13)0.958Number of fractures131210.582840.435all data in bold are statiscally significant data (p<0.05)AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; CRP, C-reactive protein; HU, Hounsfield unit; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NSAIDs, Non-steroidal anti-inflammatory drugs; SBAC-L1, scanographic bone attenuation coefficient of the first lumbar vertebra; SD, standard deviation; TNF, tumour necrosis factor; VF, vertebral fracture.Age in mSASSS + group and disease duration are in median (IQR), whereas age in general population, BASDAI, BASFI, ASDAS are in mean (± SD).

Source: Population. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Relationship between spinal structural damage on radiography and bone fragility on CT in ankylosing spondylitis patients

Study design awaiting verification · Scientific Reports · 2021

Original publication title

Relationship between spinal structural damage on radiography and bone fragility on CT in ankylosing spondylitis patients

Marine Fauny; Frank Verhoeven; Edem Allado; Eliane Albuisson; Astrid Pinzano; Caroline Morizot; Isabelle Chary-Valckenaere; Damien Loeuille

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

To evaluate whether the risk of bone fragility on computed tomography (CT) (scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1)) is associated with the severity of spine structural involvement (mSASSS) in patients with ankylosing spondylitis (AS). This retrospective study included AS patients, followed from 2009 to 2017, who fulfilled the New York criteria and who underwent thoraco-abdomino-pelvic CT and radiography (spine, pelvis). The structural involvement was retained for mSASSS ≥ 2. The SBAC-L1 was measured in Hounsfield units (HU).

A SBAC-L1 ≤ 145 HU was used to define patients at risk of vertebral fracture (VF). A total of 73 AS patients were included (mean age: 60.3 (± 10.7) years, 8 women (11%), mean disease duration: 24.6 years (± 13.9)). Sixty patients (82.2%) had a mSASSS ≥ 2 (mean score 20.7 (± 21.2)). The mean SBAC-L1 was 141.1 HU (± 45), 138.1 HU (± 44.8) and 154.8 HU (± 44.9) in the total, mSASSS ≥ 2 and mSASSS < 2 populations, respectively.

Patients with bone bridges had lower SBAC-L1 than mSASSS ≥ 2 patients without ankylosis (p = 0.02) and more often SBAC-L1 ≤ 145 HU (73% vs 41.9%, p = 0.006). A SBAC-L1 ≤ 145 HU was not associated with structural spine involvement, but patients with bone bridges had significantly decreased SBAC-L1 and an increased probability of being under the fracture threshold.

Authors’ abstract

To evaluate whether the risk of bone fragility on computed tomography (CT) (scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1)) is associated with the severity of spine structural involvement (mSASSS) in patients with ankylosing spondylitis (AS). This retrospective study included AS patients, followed from 2009 to 2017, who fulfilled the New York criteria and who underwent thoraco-abdomino-pelvic CT and radiography (spine, pelvis). The structural involvement was retained for mSASSS ≥ 2. The SBAC-L1 was measured in Hounsfield units (HU).

A SBAC-L1 ≤ 145 HU was used to define patients at risk of vertebral fracture (VF). A total of 73 AS patients were included (mean age: 60.3 (± 10.7) years, 8 women (11%), mean disease duration: 24.6 years (± 13.9)). Sixty patients (82.2%) had a mSASSS ≥ 2 (mean score 20.7 (± 21.2)). The mean SBAC-L1 was 141.1 HU (± 45), 138.1 HU (± 44.8) and 154.8 HU (± 44.9) in the total, mSASSS ≥ 2 and mSASSS < 2 populations, respectively.

Patients with bone bridges had lower SBAC-L1 than mSASSS ≥ 2 patients without ankylosis (p = 0.02) and more often SBAC-L1 ≤ 145 HU (73% vs 41.9%, p = 0.006). A SBAC-L1 ≤ 145 HU was not associated with structural spine involvement, but patients with bone bridges had significantly decreased SBAC-L1 and an increased probability of being under the fracture threshold.

Publication and source details

Original title: Relationship between spinal structural damage on radiography and bone fragility on CT in ankylosing spondylitis patients

Marine Fauny; Frank Verhoeven; Edem Allado; Eliane Albuisson; Astrid Pinzano; Caroline Morizot; Isabelle Chary-Valckenaere; Damien Loeuille

Scientific Reports · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T12:54:13.024263+00:00

DOI: 10.1038/s41598-021-88838-9 · PMC8085178